| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Research and development (including related party amounts of 13, 1,342, 63 and 2,802, respectively) | 17,633 | 17,861 | 17,052 | 13,524 |
| General and administrative | 5,264 | 4,949 | 5,119 | 4,811 |
| Total operating expenses | 22,897 | 22,810 | 22,171 | 18,335 |
| Change in fair value of safes (including related party amounts of 2,911 and 0, respectively) | - | - | - | -977 |
| Loss from operations | -22,897 | -22,810 | -22,171 | -18,335 |
| Interest income | 1,372 | 1,561 | 1,864 | 1,846 |
| Other (expense) income, net | -3 | -5 | -4 | -6 |
| Total other income (expense), net | 1,369 | 1,556 | 1,860 | 863 |
| Net loss | -21,528 | -21,254 | -20,311 | -17,472 |
| Unrealized gain (loss) on investments, net | - | 2 | 129 | 217 |
| Unrealized gain on investments, net | 85 | - | - | - |
| Comprehensive loss | -21,443 | -21,252 | -20,182 | -17,255 |
| Earnings per share, basic | -0.88 | -0.87 | -0.83 | -0.92 |
| Earnings per share, diluted | -0.88 | -0.87 | -0.83 | -0.92 |
| Weighted average number of shares outstanding, basic | 24,481,722 | 24,378,823 | 24,341,978 | 18,896,829 |
| Weighted average number of shares outstanding, diluted | 24,481,722 | 24,378,823 | 24,341,978 | 18,896,829 |
Artiva Biotherapeutics, Inc. (ARTV)
Artiva Biotherapeutics, Inc. (ARTV)